Online inquiry

IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ8426MR)

This product GTTS-WQ8426MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets HSP90 gene. The antibody can be applied in Candidiasis research.

Specifications
Product type	mRNA
Modified bases	2-Thio-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	XP_721353.1
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3636951
UniProt ID	P46598

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8426MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ5772MR	IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	cetuximab-IR700
GTTS-WQ11123MR	IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	MDX-1103
GTTS-WQ187MR	IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	12-IgG1
GTTS-WQ15478MR	IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	UCB-0107
GTTS-WQ2118MR	IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	Alb-IFNA2 R23 (608)
GTTS-WQ15877MR	IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	XMT-1536
GTTS-WQ14128MR	IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	aPCSK927
GTTS-WQ10965MR	IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MCAF-5352A

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST